| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728222.2014.995093 |
| P698 | PubMed publication ID | 25532429 |
| P2093 | author name string | Yi-Long Wu | |
| Anna Li | |||
| Hong-Fei Gao | |||
| P2860 | cites work | Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer | Q47992122 |
| BRAF-mutations in non-small cell lung cancer | Q50720262 | ||
| c-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas | Q53196482 | ||
| PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers | Q53486364 | ||
| MET expression plays differing roles in non-small-cell lung cancer patients with or without EGFR mutation | Q54360908 | ||
| Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance. | Q55284672 | ||
| Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 | ||
| Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors | Q24339620 | ||
| The MET axis as a therapeutic target | Q24609682 | ||
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 | ||
| Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
| MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis | Q26823626 | ||
| Prognostic significance of MET amplification and expression in gastric cancer: a systematic review with meta-analysis | Q27027981 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification | Q27851651 | ||
| ROS1 rearrangements define a unique molecular class of lung cancers | Q27851700 | ||
| Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma | Q27851979 | ||
| Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement | Q27852650 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| c-Met: structure, functions and potential for therapeutic inhibition | Q28190143 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Comprehensive molecular profiling of lung adenocarcinoma | Q28244995 | ||
| A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo | Q28270305 | ||
| Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer | Q28534819 | ||
| Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer | Q33607176 | ||
| New driver mutations in non-small-cell lung cancer | Q34161395 | ||
| Scatter factors and invasive growth | Q34231968 | ||
| Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. | Q34307548 | ||
| c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention | Q34422211 | ||
| Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients | Q34446136 | ||
| Dysregulation of Met receptor tyrosine kinase activity in invasive tumors | Q34584046 | ||
| Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer | Q35010777 | ||
| MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib | Q35666332 | ||
| Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer | Q35983145 | ||
| Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. | Q36384594 | ||
| Activating mutations for the Met tyrosine kinase receptor in human cancer | Q36595980 | ||
| MET As a Possible Target for Non–Small-Cell Lung Cancer | Q36660673 | ||
| A germline variant N375S in MET and gastric cancer susceptibility in a Chinese population | Q36732888 | ||
| Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy | Q36828371 | ||
| Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer | Q36878125 | ||
| Lack of Association of C-Met-N375S Sequence Variant with Lung Cancer Susceptibility and Prognosis | Q36953116 | ||
| Expression and mutational analysis of MET in human solid cancers | Q36975055 | ||
| Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer | Q37111358 | ||
| MET as a target for treatment of chest tumors | Q37232416 | ||
| MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. | Q37321772 | ||
| MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors | Q37399525 | ||
| Ethnic differences and functional analysis of MET mutations in lung cancer | Q37399540 | ||
| Clinical implications of MET gene copy number in lung cancer | Q37690299 | ||
| Hepatocyte growth factor activator (HGFA): pathophysiological functions in vivo | Q37733681 | ||
| MET Signaling: Novel Targeted Inhibition and Its Clinical Development in Lung Cancer | Q37975092 | ||
| Targeting the MET gene for the treatment of non-small-cell lung cancer | Q38172700 | ||
| cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients? | Q38236096 | ||
| Mechanisms of hepatocyte growth factor activation in cancer tissues | Q38255480 | ||
| Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. | Q38409218 | ||
| Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival | Q38441644 | ||
| MiR-181a-5p is downregulated in hepatocellular carcinoma and suppresses motility, invasion and branching-morphogenesis by directly targeting c-Met | Q38972160 | ||
| Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology | Q39027803 | ||
| Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. | Q39315725 | ||
| Activation of ERK–p53 and ERK-Mediated Phosphorylation of Bcl-2 Are Involved in Autophagic Cell Death Induced by the c-Met Inhibitor SU11274 in Human Lung Cancer A549 Cells | Q39370977 | ||
| EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers | Q39430432 | ||
| Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth | Q39472261 | ||
| A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3 | Q39473718 | ||
| Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer | Q39911616 | ||
| Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. | Q39985982 | ||
| MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. | Q40108065 | ||
| Somatic mutations lead to an oncogenic deletion of met in lung cancer | Q40333112 | ||
| Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. | Q40453775 | ||
| Two mutations affecting conserved residues in the Met receptor operate via different mechanisms | Q42621322 | ||
| MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations | Q42731321 | ||
| Novel mutations of the MET proto-oncogene in papillary renal carcinomas. | Q42815807 | ||
| Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status | Q43164574 | ||
| Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers | Q43598203 | ||
| MET and phosphorylated MET as potential biomarkers in lung cancer | Q45329018 | ||
| Molecular cloning of a new transforming gene from a chemically transformed human cell line. | Q45345810 | ||
| Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. | Q45933831 | ||
| Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. | Q46043057 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 663-674 | |
| P577 | publication date | 2014-12-23 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Expert Opinion on Therapeutic Targets | Q5421214 |
| P1476 | title | Targeting the MET pathway for potential treatment of NSCLC. | |
| P478 | volume | 19 |
| Q47138727 | AKIP1 promoted epithelial-mesenchymal transition of non-small-cell lung cancer via transactivating ZEB1. |
| Q41709320 | BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells |
| Q59808389 | Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression |
| Q37427045 | MEK inhibitors against MET-amplified non-small cell lung cancer |
| Q26786580 | Novel targeted agents for the treatment of lung cancer in China |
| Q64079089 | Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways |
| Q37457584 | Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer |
| Q55345918 | Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis. |
| Q46113966 | TGF-β1 Signaling and Tissue Fibrosis |
Search more.